Q-omics provides the consensus-scored GRIP2 profile across patient tissues and cancer cell-line models. GRIP2 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, GRIP2 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, GRIP2 RNA expression shows 16,519 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, KIRC, and UVM as cancer lineages where GRIP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GRIP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GRIP2 survival associations across molecular data types. GRIP2 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GRIP2 RNA expression–survival associations across cancer types. High GRIP2 expression shows favorable associations in HNSC, KICH, ESCA, SKCM, LUAD and READ. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for GRIP2 RNA expression.
This table summarizes GRIP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for GRIP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GRIP2 shows lower tumor expression in KIRC, KIRP, THCA, KICH, BRCA and UCEC. The KIRC box plot shows higher GRIP2 RNA expression in normal versus tumor tissue (log2 FC = −0.663, t-test p < 0.001).
This table shows molecular features associated with GRIP2 in patient tissues and cancer cell lines. In patient samples, GRIP2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, GRIP2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LUNG_NSCLC_LUSC.
